exoVACC based vaccine / Codiak, Ragon Institute - LARVOL DELTA

Codiak BioSciences collaborates with Ragon Institute to evaluate the exoVACC vaccine platform in SARS-CoV-2 and HIV (Businesswire) - "Codiak BioSciences, Inc....today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of its exoVACC vaccine platform in (1) SARS-CoV-2, the virus that causes COVID-19....Codiak researchers will work with Bruce Walker...and Gaurav Gaiha...of the Ragon Institute to build integrated exosome-based vaccines aimed at inducing broad neutralizing antibody and antigen-specific T cell protection against the viruses."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease